Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Wilbert Zwart
Affiliation
Oncode Institute, The Netherlands Cancer Institute
ORCID
Career Start Year
2004
Papers
147
H Index
40
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
37854018
Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-NDRG1 deregulation.
Mol Oncol
2024
36669105
Mammalian life depends on two distinct pathways of DNA damage tolerance.
Proc Natl Acad Sci U S A
2023
37961147
Breast cancer risk SNPs converge on estrogen receptor binding sites commonly shared between breast tumors to locally alter estrogen signalling output.
bioRxiv
2023
37554550
Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.
Cancer Res Commun
2023
37902007
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
EMBO Mol Med
2023
37791849
Compartmentalization of androgen receptors at endogenous genes in living cells.
Nucleic Acids Res
2023
37694973
Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in Prostate Cancer.
Cancer Discov
2023
37578563
Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.
Cell Mol Life Sci
2023
37733591
Perturbations in 3D genome organization can promote acquired drug resistance.
Cell Rep
2023
37535891
Inhibiting the Glucocorticoid Receptor to Enhance Chemotherapy Response.
J Clin Oncol
2023
37770115
TRIM25 targets p300 for degradation.
Life Sci Alliance
2023
37370685
Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.
Cancers (Basel)
2023
37271632
Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.
Eur Urol
2023
37070193
PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.
Nucleic Acids Res
2023
37333335
A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.
bioRxiv
2023
37397353
<i>snHiC</i>: a complete and simplified snakemake pipeline for grouped Hi-C data analysis.
Bioinform Adv
2023
36900323
The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers.
Cancers (Basel)
2023
34446849
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.
Prostate Cancer Prostatic Dis
2022
35509021
Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.
Clin Epigenetics
2022
35754340
Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.
Cancer Discov
2022
35523804
Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.
NPJ Breast Cancer
2022
36450752
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.
Nat Commun
2022
35871293
HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia.
Nucleic Acids Res
2022
36107780
Double-strand break toxicity is chromatin context independent.
Nucleic Acids Res
2022
36107324
Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.
Adv Exp Med Biol
2022
36071171
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.
Nat Genet
2022
36125208
Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.
Endocrinology
2022
36323660
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.
Nat Commun
2022
35918345
Ribosome impairment regulates intestinal stem cell identity via ZAKÉ¿ activation.
Nat Commun
2022
36251389
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
Cancer Res
2022
34927791
Unexpected gene activation following CRISPR-Cas9-mediated genome editing.
EMBO Rep
2022
33328650
Genomic and phenotypic heterogeneity in prostate cancer.
Nat Rev Urol
2021
33576154
Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.
Mol Oncol
2021
33852423
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?
Endocr Relat Cancer
2021
33753731
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.
NPJ Breast Cancer
2021
33531470
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Nat Commun
2021
33751115
Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites.
Nucleic Acids Res
2021
34944934
Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.
Cancers (Basel)
2021
34737261
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.
Nat Commun
2021
34671036
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.
NPJ Breast Cancer
2021
34489572
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.
Nat Cell Biol
2021
34503156
Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation.
Cancers (Basel)
2021
34131070
The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.
Mol Cancer Res
2021
34272384
Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.
Nat Commun
2021
34211036
A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.
Sci Rep
2021
34208621
TRIMming Down Hormone-Driven Cancers: The Biological Impact of TRIM Proteins on Tumor Development, Progression and Prognostication.
Cells
2021
33975627
Functional mapping of androgen receptor enhancer activity.
Genome Biol
2021
33462444
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.
Nat Med
2021
33452241
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.
Nat Commun
2021
33358533
Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer.
Mol Aspects Med
2021
1 - 50 of 147
Column Actions
Search
Recommended Authors
Yunpeng Gao
University of Texas Southwestern Medical Center at Dallas
Career Start Year
2017
Number of shared co-authors
2
Wei Yuan
The Institute for Cancer Research
Career Start Year
2015
Number of shared co-authors
15
Yu-Jia Shiah
Ontario Institute for Cancer Research
Career Start Year
2015
Number of shared co-authors
28
Joshua Armenia
Oncology R&D
Career Start Year
2013
Number of shared co-authors
17
Matthew Ung
Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth
Career Start Year
2013
Number of shared co-authors
0
Haiyang Guo
the Second Hospital, Cheeloo College of Medicine, Shandong University
Career Start Year
2011
Number of shared co-authors
28
Susmita G Ramanand
UT Southwestern Medical Center
Career Start Year
2010
Number of shared co-authors
19
Mandeep Takhar
GenomeDx Biosciences Inc.
Career Start Year
2010
Number of shared co-authors
25
Jeffery M Vahrenkamp
Huntsman Cancer Institute
Career Start Year
2010
Number of shared co-authors
0
Alfonso Urbanucci
Northwestern University Feinberg School of Medicine Chicago
Career Start Year
2008
Number of shared co-authors
20
Dimple Chakravarty
Icahn School of Medicine at Mount Sinai
Career Start Year
2007
Number of shared co-authors
9
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year
2005
Number of shared co-authors
8
Gong-Hong Wei
Fudan University Shanghai Cancer
Career Start Year
2004
Number of shared co-authors
17
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year
2003
Number of shared co-authors
7
Genevi??ve Deblois
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year
2003
Number of shared co-authors
10
Jason Gertz
Huntsman Cancer Institute, University of Utah
Career Start Year
2003
Number of shared co-authors
1
Charlie E Massie
University of Cambridge
Career Start Year
2003
Number of shared co-authors
9
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Career Start Year
2002
Number of shared co-authors
7
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year
2002
Number of shared co-authors
8
Joshua Chuck Harrell
Virginia Commonwealth University
Career Start Year
2002
Number of shared co-authors
0
Syed Haider
Institute of Cancer Research
Career Start Year
2002
Number of shared co-authors
19
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year
2001
Number of shared co-authors
5
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year
2001
Number of shared co-authors
9
David S Rickman
Meyer Cancer Center
Career Start Year
2001
Number of shared co-authors
19
Nadia Boufaied
Research Institute of the McGill University Health Centre
Career Start Year
2000
Number of shared co-authors
11
Tim H-M Huang
University of Texas Health San Antonio (UTHSA)
Career Start Year
1997
Number of shared co-authors
2
Ian G Mills
Queen's University Belfast
Career Start Year
1997
Number of shared co-authors
18
Cecilia Williams
Karolinska Institutet
Career Start Year
1997
Number of shared co-authors
0
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year
1993
Number of shared co-authors
57
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year
1991
Number of shared co-authors
9
row(s) 1 - 30 of 30
Collaborators
Andries M Bergman
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
Co-authored papers
38
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Co-authored papers
30
Tesa M Severson
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers
17
Jason S Carroll
Co-authored papers
15
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Co-authored papers
8
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers
8
Sander Canisius
The Netherlands Cancer Institute
Co-authored papers
7
Yanyun Zhu
Jiangsu Collaborative Innovation Center for Solid Organic Waste Resource Utilization
Co-authored papers
7
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers
7
Paul J van Diest
University Medical Center Utrecht
Co-authored papers
5
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers
5
Martin E Gleave
University of British Columbia
Co-authored papers
4
Daniel S Peeper
Netherlands Cancer Institute
Co-authored papers
4
Mark M Pomerantz
Dana-Farber Cancer Institute
Co-authored papers
4
Oscar Krijgsman
The Netherlands Cancer Institute
Co-authored papers
4
Sylvan C Baca
Co-authored papers
4
Bogdan Pasaniuc
David Geffen School of Medicine, University of California los angeles
Co-authored papers
4
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers
4
Paul C Boutros
University of California los angeles
Co-authored papers
4
Amina Zoubeidi
University of British Columbia
Co-authored papers
4
Takafumi N Yamaguchi
University of California los angeles
Co-authored papers
3
Giacomo Grillo
Princess Margaret Cancer Centre, University Health Network
Co-authored papers
3
Luke A Selth
Adelaide Medical School, University of Adelaide
Co-authored papers
3
Michiel S van der Heijden
the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
Co-authored papers
3
Mark A Rubin
University of Bern
Co-authored papers
3
Stanley Zhou
Princess Margaret Cancer Research Centre
Co-authored papers
3
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Co-authored papers
3
Faraz Hach
University of British Columbia
Co-authored papers
3
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Co-authored papers
3
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers
3
1 - 30